Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109628 | 0.85 | — | — | |
| SCHEMBL5069754 | 0.79 | ALDH1A1 (0.50) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL916463 | 0.79 | SLC18A3 (0.48) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL16109491 | 0.78 | SLC18A3 (0.44) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL1569807 | 0.78 | — | — | |
| SCHEMBL15582715 | 0.77 | SLC18A3 (0.47) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL3951308 | 0.77 | SLC18A3 (0.47) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL1316226 | 0.77 | SLC18A3 (0.47) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL916237 | 0.77 | GNAI3 (0.50) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL91689 | 0.77 | CARM1 (0.56) | SLC18A3ALDH1A1KDM4EKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-02-02 | — | — | US | claimed |
| US-9499522-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-11-22 | — | — | US | claimed |
| EP-2970231-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | Blueprint Medicines Corporation (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160521-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | US | claimed |
| US-9994552-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-9499522-B2 | Compositions useful for treating disorders related to kit | BLUEPRINT MEDICINES CORPORATION (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2970231-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | Blueprint Medicines Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160521-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS KIT MODULATORS | BLUEPRINT MEDICINES CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| CN-101321748-B | Isoquinoline derivatives | ORGANON NV | 2013-03-27 | — | — | CN | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SLC18A3 3773/4885ALDH1A1 2630/4885KDM4E 915/4885 |
| US-20140296206-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, CKMT1A; CKMT1B | SLC18A3 2136/4885ALDH1A1 629/4885KDM4E 2952/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | SLC18A3 4321/4885ALDH1A1 2281/4885KDM4E 1195/4885 |
| US-20170029409-A1 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT | KIT, APC, CKMT1A; CKMT1B | SLC18A3 2136/4885ALDH1A1 629/4885KDM4E 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.